You are here: Industry Insights > Pancreatic cancer

News List

OBI Pharma Granted Orphan Drug Designation for ADC Targeted Cancer Therapy americanpharmaceuticalreview
January 06, 2020
OBI Pharma announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Pancreatic Cancer. OBI-999 is a first-in-class antibody drug conjugate targeting Globo H, a glycolipid antigen.
AZ, Merck's Lynparza lands FDA nod in pancreatic cancer fiercepharma
January 03, 2020
Earlier this month, FDA experts voted—barely—that the agency should approve AstraZeneca and Merck’s Lynparza in pancreatic cancer.
FDA advisory committee backs Lynparza use for pancreatic cancer pharmaceutical-technology
December 19, 2019
The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca-Merck (MSD)’s Lynparza (olaparib) to treat ...
Is AZ, Merck's Lynparza approvable in pancreatic cancer? fiercepharma
December 17, 2019
When AstraZeneca and Merck & Co. unveiled in February that a study of Lynparza in pancreatic cancer had read out positively, there was much excitement in the oncology world.
AZ/Merck & Co’s Lynparza delays spread of pancreatic cancer pharmaphorum
February 27, 2019
AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.
AbbVie and J&J’s Imbruvica fails pancreatic cancer test pharmaphorum
January 23, 2019
AbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has hit a snag.
Altering the Supportive Structure of Pancreatic Cancer Tissue May Unlock Promising Therapies firstwordpharma
January 09, 2019
Pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most lethal cancer in the U.S. by 2020, but Fox Chase Cancer Center researchers are exploring the structural mechanisms that allow these cancer cells to spread, and a new paper sugge
Chemo 'Cocktail' Embraced as Pancreatic Cancer Breakthrough drugs
December 20, 2018
When researchers announced that a four-drug chemotherapy regimen can add years to the lives of some patients with earlier-stage pancreatic cancer, doctors didn't wait.....
BioLineRx Announces Initiation of Triple Combination Arm of Pancreatic Cancer Study americanpharmaceuticalreview
December 12, 2018
BioLineRx announced the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in patients with metastatic pancreatic cancer (PDAC) under its immuno-oncology.....
GSK begins clinical trials of pancreatic cancer combination pharmaphorum
December 03, 2018
GlaxoSmithKline plans to carry out clinical trials on its pancreatic drug hopeful, GSK547, following promising results when treating mice and laboratory-grown tumour cells.

Previous page 1 2 3 4 5 6 Next page